CN117377472A - 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌 - Google Patents

使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌 Download PDF

Info

Publication number
CN117377472A
CN117377472A CN202280015198.3A CN202280015198A CN117377472A CN 117377472 A CN117377472 A CN 117377472A CN 202280015198 A CN202280015198 A CN 202280015198A CN 117377472 A CN117377472 A CN 117377472A
Authority
CN
China
Prior art keywords
gdc
patient
combination therapy
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280015198.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·梅特卡夫
王晓晶
周维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN117377472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN117377472A publication Critical patent/CN117377472A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280015198.3A 2021-02-16 2022-02-14 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌 Pending CN117377472A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
US63/149,944 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (1)

Publication Number Publication Date
CN117377472A true CN117377472A (zh) 2024-01-09

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280015198.3A Pending CN117377472A (zh) 2021-02-16 2022-02-14 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌

Country Status (8)

Country Link
US (1) US20230381155A1 (https=)
EP (1) EP4294395B1 (https=)
JP (1) JP2024506385A (https=)
CN (1) CN117377472A (https=)
ES (1) ES3030540T3 (https=)
PL (1) PL4294395T3 (https=)
TW (1) TWI808648B (https=)
WO (1) WO2022177844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202541794A (zh) * 2022-11-02 2025-11-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
TW202011966A (zh) * 2018-07-23 2020-04-01 瑞士商赫孚孟拉羅股份公司 用pi3k抑制劑gdc-0077治療癌症之方法
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
CA3169679A1 (en) * 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases

Also Published As

Publication number Publication date
WO2022177844A1 (en) 2022-08-25
EP4294395B1 (en) 2025-03-26
JP2024506385A (ja) 2024-02-13
PL4294395T3 (pl) 2025-06-23
EP4294395C0 (en) 2025-03-26
US20230381155A1 (en) 2023-11-30
TWI808648B (zh) 2023-07-11
TW202237100A (zh) 2022-10-01
EP4294395A1 (en) 2023-12-27
ES3030540T3 (en) 2025-06-30

Similar Documents

Publication Publication Date Title
US12083129B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
US20260041695A1 (en) Combination therapies for treatment of breast cancer
US20230381155A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
TWI800827B (zh) 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
WO2018138510A1 (en) Mebendazole for use in the treatment of cancer
TWI881203B (zh) 使用包含gdc-9545及帕他色替之組合療法治療乳癌
EP4630002A1 (en) Cancer therapy with capivasertib and fulvestrant
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
HK40098151A (zh) 使用包括gdc-9545以及阿贝西利或者瑞博西尼的组合疗法治疗乳腺癌
HK40129153A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40084792B (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101173

Country of ref document: HK